VISOMITIN cataract eye drops - Revolutionary eye drops
If you are not aware what is it, please use google, there are plenty info about this new drug. This drops are available only in Russia and you can get it at any drug store/pharmacy over there. Shipping any drugs is impossible from Russia due to its customs regulations, so we do our best efforts to bring this unique medicine to the people in North and South America who are in needs of it.
You must use only 1-2 drops per each eye 3 times a day (no more and no less)
You always MUST begin treatment with 1 drop per eye for first 7 days of use!!!
Before using drops you must SHAKE a liltle bit your bottle for few sec.
You must STORE drops ALL TIMES at the cold and dark place with the temperature between 5-6 Degree Celsius C / 41-43F
The length of use must be at least 3 full weeks in order to see first signs of progress!
A bit pre-history: At the turn of 1960-1970s, in 1969 V.Skulachev and his Moscow State University (MSU) colleagues, in collaboration with Prof. Yefim Liberman’s team (USSR Academy of science) were verifying the chemiosmotic hypothesis proposed by Dr. Peter Mitchell (Nobel Prize Winner in Chemistry, 1978) who postulated the existence of electric potential difference across the mitochondrial membrane. The results of their work (published in Nature, 1969, 222, 1076-8) suggested that some compounds - lipophilic cations (phosphonium ions for instance) – can be targeted to mitochondria due to the electric field on the mitochondrial membrane as the mitochondrion has a negative charge inside. Those scientists developed a general approach that led to synthesis of hydrophobic ions capable of penetrating mitochondrial membrane.
Mitochondria are well known to be organelles present in practically every eukaryotic cell. Mitochondria can be called the power stations of living cells. Inside mitochondria the electric potential formed by respiratory chain enzymes through oxidative degradation of nutrients is transformed into the energy of ATP (adenosine triphosphate) chemical bonds.
A substantial negative charge is formed inside mitochondria in the process of electric potential difference generation on the mitochondrial membrane. It is important to stress that the inner mitochondrial space is the only place in living cell which is negatively charged in relation to its external environment.
This unique mitochondrial feature was suggested to be used for targeted accumulation of positively charged substances in mitochondria. Positively charged ions (cations), were hypothesized to be accumulated in mitochondria after getting into a cell. In order to verify this hypothesis cations of triphenylalkylphosphonium (TPP) were studied. Positively charged phosphorus atom is surrounded by hydrophobic residues in TPP. The charge is evenly distributed through the whole space around the central atom in this type of ions. Such a construction prevents ion hydration, the main reason of membrane’s impermeability for charged molecules. TPP cations proved to get accumulated in mitochondria.
Back in 1970 S.Severin, V.Skulachev and L.Yaguzhinsky suggested to use penetrating ions as “electric locomotive molecules” capable of transporting into mitochondria different substances that would be able to influence processes taking place in these organelles. Back in 1974 American biochemist David Green suggested this type of penetrating cations to be called “Skulachev ions” or “Sk”.
At the end of the 90s British scientist from Cambridge Michael Murphy connected TPP ions to antioxidants – vitamin E and ubiquinone. This work was part of the same concept of molecular electric locomotives capable of targeted transport of different substances into mitochondria. The data of Murphy et al proved MitoQ (the name given to this new substance - ubiquinone attached to TPP) to actually get accumulated in mitochondria, which resulted in protection of mitochondria and cell cultures from oxidative stress. But so far it hasn’t been possible to use these substances on a wider scale, most likely because of a strong pro-oxidant activity and lack of effectiveness in small concentrations.
Some new possibilities opened up only in the beginning of this century. In 2004, a new substance was synthesized by the group of professor Vladimir P. Skulachev in the Moscow State University and the project team later gave the substance its “production” name “SkQ1". The name SkQ1 was given to the substance as the first representative of a particularly potent class of molecules named “SkQ” – the term introduced by the team to describe molecules containing ion Sk an a quinone.
A part of SkQ1 coined “Skulachev ion” or Sk functions as a molecular “locomotive” or “towing truck” carrying the other part of the molecule – an extremely active antioxidant plastoquinone – into mitochondria. Both theoretical calculations and experimental results showed that SkQ1 is delivered into mitochondria in an extremely targeted and efficient manner. The physics of mitochondrial membrane and the unusual properties of “Skulachev ions” direct SkQ1 into the inner leaflet of the inner mitochondrial membrane with high precision.
Presence of SkQ1 in mitochondrial membrane enables mitochondria to protect itself from reactive oxygen species (ROS) by breaking chain reaction of lipid destruction. This ability of our molecule to protect cells against oxidative stress plays a very important role in treating patients suffering from various age-related disorders such as cardiovascular diseases, neurodegenerative disorders and various ophthalmic conditions.
But technology does not end there. Developing methods for effective delivery of mitochondrially addressed antioxidants into organism is another challenging task. Mitotech successfully solved this complex problem for a variety of therapeutic areas and designed several SkQ1-based pharmaceutical products going through various stages of clinical development.
Reactive oxygen species, ROS, include oxygen ions, free radicals and peroxides of both organic and nonorganic origin. As a rule those are small molecules that possess a very high ability to interact with other substances (to oxidize them) due to the presence of an unpaired electron in the outer shell.
ROS are known to present serious danger for living cells and whole organisms (even though under certain conditions they can also fulfill some important cell functions, e.g. participate in regulation).
The primary forms of ROS are superoxide (O2-.) and its derivative hydrogen peroxide (H2O2). And even though a number of enzymes responsible for transformation of O2 into the primary forms of ROS were discovered in living cells, all of them proved to produce far less ROS than the respiratory chain of the inner mitochondrial membrane. Mitochondria of an adult absorb about 400 liters of oxygen per day converting it to water in the process of four- electron reduction. At the same time if even 0,1% of this oxygen reduction takes place in a chemically more simple single electron manner, it will result in 0,4 liters O2-., and this amount proves to exceed substantially all the other possibilities of ROS generation mechanisms. Experimental data prove these calculations to be true. In other words mitochondria constantly produce the amount of ROS sufficient to oxidize cell DNA, proteins and lipids thus causing their damage.
It has been hypothesized that age-dependent accumulation of oxidative damages in living organisms may be the main cause of ageing process. It might be possible to control this damage accumulation through controlling the level of ROS production in mitochondria. It is important to stress that ROS production should be controlled, not stopped, so that ROS can still fulfill a number of crucial biological functions. For instance they fight bacteria and viruses, both directly – via elimination of pathogens, – and indirectly – via regulation of the immunological response to infection through triggering apoptosis (cell death).
Antioxidants are a well−developed pharmacological approach to fight against ROS. A possible role of antioxidants in controlling ageing process has widely and for a long time been discussed with ambiguous conclusions, ranging from the statement of the American biochemist Prof. Bruce Ames and colleagues on finding a new anti−ageing therapy with a 100% positive result to D. Howes’s implication of the utter barrenness of this method, and, therefore, of total failure of Harman’s “free radical” hypothesis. According to Dr. Skulachev the antioxidant−based ageing control approach has some significant flaws.
The “ideal” antioxidant should be specifically targeted to mitochondria where ROS are produced and it should effectively remove not all the ROS but just their excess. It is also important for an antioxidant not to be toxic and not to be recognized and eliminated by cell enzymes.
With these criteria fulfilled, a successful anti-oxidant compound is able to prevent/repair oxidative damage in organism and prevent/treat many age-related disorders across various therapeutic areas.
In pharmacology, the term mechanism of action (MOA) refers to the specific biochemical interaction through which a drug substance produces its pharmacological effect. Usually a new pharmaceutical substance is designed in such a way that it is capable of initiating on a well-known biochemical reaction in the organism.
The design process for SkQ1 was dramatically different. The mechanism of action of SkQ1 involves at least two extremely complex and novel concepts: delivering a compound inside mitochondria and reducing ROS production inside mitochondria in a controlled and sustainable manner. SkQ1 molecule successfully addresses these two aspects as our experimental work has shown.
And unlike the most of conventional drugs, SkQ1 is capable of treating a variety of seemingly different disorders across all therapeutic areas. SkQ1 has been shown to be quite effective in many conditions attributable to ageing process from ophthalmology to neurodegeneration and CV disorders. Proven recent clinical studies demonstrated such effects.
At this point it was clinically proven to use for:
- it treats cataracts and glaucoma, including their most bad choices
- uses for enteral inflammations
Dry Eye Syndrome Visomitin (2 Units, 2x5ml)
- Product Code: Visomitin 5 ml
- Availability: In Stock
- Ex Tax: $99.00